Rights and permissions
About this article
Cite this article
G-CSF: lack of added benefit in AML. Inpharma Wkly. 1439, 11 (2004). https://doi.org/10.2165/00128413-200414390-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200414390-00025